Genomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels

<div>Homozygous deletions involving the<i> CDKN2A</i> and<i> CDKN2B</i> genes at chromosome 9p21.3 detected in LMS2 and SKN. A 7.5 Mb region (Chr9: 20,908,374–28,420,020, hg19) and a 0.5 Mb region (Chr9: 21,695,893-22,195,820, hg19) were found to be homozygously deleted in LMS2 (a) and in SKN (b), respectively.</div>

Sarcoma

fig2

Figure 2

Figure 2: Genomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels 

Figure 2 | Genomic, Epigenomic, and Transcriptomic Profiling towards Identifying Omics Features and Specific Biomarkers That Distinguish Uterine Leiomyosarcoma and Leiomyoma at Molecular Levels 